StreetInsider.com News Articles

Caris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026

Thu, 16 Jul 2026 08:30:00 -0400

IRVING, Texas, July 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced it will report second quarter 2026 financial results on Wednesday, August 5, 2026.

Caris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026

Thu, 16 Jul 2026 08:30:00 -0400

Caris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026

Thu, 16 Jul 2026 08:30:00 -0400

Caris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026

Thu, 16 Jul 2026 08:30:00 -0400

Caris Life Sciences to offer PTEN IHC testing for prostate cancer

Tue, 14 Jul 2026 08:31:59 -0400

Caris Life Sciences (NASDAQ: CAI) announced it will offer in-house PTEN immunohistochemistry (IHC) testing following the FDA approval of capivasertib, in combination with abiraterone and prednisone, for adults with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive prostate cancer.

The testing is designed to identify patients whose tumors exhibit PTEN protein loss, a molecular alteration associated with activation of the PI3K/AKT pathway. According to the company, one in four patients with this form of prostate cancer have PTEN-deficient tumors. Prostate cancer accounts for more than 300,000 new diagnoses annually in the United States.

Testing will be performed within Caris' CAP-accredited, CLIA-certified laboratories. The

Caris Life Sciences Expands Precision Oncology in Metastatic Prostate Cancer with PTEN IHC Testing

Tue, 14 Jul 2026 08:30:00 -0400

IRVING, Texas, July 14, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced it will offer in-house PTEN immunohistochemistry (IHC) testing following the recent FDA approval of a biomarker-guided therapy and companion diagnostic assay. This testing is designed to help identify patients with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously known as metastatic hormone-sensitive prostate cancer) who are eligible for the newly approved biomarker-guided therapy, representing a significant advancement in precision

Caris Life Sciences Expands Precision Oncology in Metastatic Prostate Cancer with PTEN IHC Testing

Tue, 14 Jul 2026 08:30:00 -0400

Caris Life Sciences Expands Precision Oncology in Metastatic Prostate Cancer with PTEN IHC Testing

Tue, 14 Jul 2026 08:30:00 -0400

Caris Life Sciences Expands Precision Oncology in Metastatic Prostate Cancer with PTEN IHC Testing

Tue, 14 Jul 2026 08:30:00 -0400

Caris Life Sciences Inc (CAI) PT Raised to $23 at Baird

Mon, 13 Jul 2026 07:18:00 -0400

Baird analyst Catherine Schulte raised the price target on Caris Life Sciences Inc (NASDAQ: CAI) to $23.00 (from $22.00) while maintaining a Outperform rating.

Form 4 Caris Life Sciences, For: May 15 Filed by: HALBERT JON

Mon, 13 Jul 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260713/26759637.html

Form 4 Caris Life Sciences, For: May 15 Filed by: HALBERT JON

Mon, 13 Jul 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260713/26759637.html

BTIG Reiterates Buy Rating on Caris Life Sciences Inc (CAI)

Thu, 02 Jul 2026 06:16:26 -0400

BTIG analyst Mark Massaro reiterated a Buy rating and $32.00 price target on Caris Life Sciences Inc (NASDAQ: CAI).

The analyst commented: "Shares of CAI advanced by 5% (in a positive healthcare tape, up slightly above peers) after the news that Caris launched Caris Detect, and has entered the early cancer detection (screening) market, in line with the company's plans. Rather than go after one cancer type (like CRC), Caris enters the multi-cancer early detection (MCED) market where the Galleri test from GRAIL (GRAL, Not Rated) is the current market leader. The MCED space remains quite nascent, and we believe that

Caris Life Sciences Launches Caris Detect, the World's Most Sensitive and Comprehensive Multi-Cancer Early Detection Blood Test

Wed, 01 Jul 2026 08:30:00 -0400

Ultra-deep Whole Genome and Whole Transcriptome sequencing combined with sophisticated AI algorithms
delivers superior performance to existing cancer detection technologies

IRVING, Texas, July 1, 2026 /PRNewswire/ -- Caris Life Sciences^® (NASDAQ: CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the commercial launch of Caris Detect™, a groundbreaking multi-cancer early detection blood test designed to uncover cancer signals at earlier, more treatable stages.

Caris Life Sciences Launches Caris Detect, the World's Most Sensitive and Comprehensive Multi-Cancer Early Detection Blood Test

Wed, 01 Jul 2026 08:30:00 -0400

Ultra-deep Whole Genome and Whole Transcriptome sequencing combined with sophisticated AI algorithms
delivers superior performance to existing cancer detection technologies

Caris Life Sciences Launches Caris Detect, the World's Most Sensitive and Comprehensive Multi-Cancer Early Detection Blood Test

Wed, 01 Jul 2026 08:30:00 -0400

Ultra-deep Whole Genome and Whole Transcriptome sequencing combined with sophisticated AI algorithms
delivers superior performance to existing cancer detection technologies

Caris Life Sciences Launches Caris Detect, the World's Most Sensitive and Comprehensive Multi-Cancer Early Detection Blood Test

Wed, 01 Jul 2026 08:30:00 -0400

Ultra-deep Whole Genome and Whole Transcriptome sequencing combined with sophisticated AI algorithms
delivers superior performance to existing cancer detection technologies

Form CERT Caris Life Sciences,

Tue, 16 Jun 2026 11:10:00 -0400

si-local-file:///var/storage/secattach/20260616/26652480.html

Form CERT Caris Life Sciences,

Tue, 16 Jun 2026 11:10:00 -0400

si-local-file:///var/storage/secattach/20260616/26652480.html

Form 8-A12B Caris Life Sciences,

Tue, 16 Jun 2026 10:47:00 -0400

si-local-file:///var/storage/secattach/20260616/26652346.html

Form 8-A12B Caris Life Sciences,

Tue, 16 Jun 2026 10:47:00 -0400

si-local-file:///var/storage/secattach/20260616/26652346.html

Caris Life Sciences dual-lists on NYSE Texas under CAI ticker

Tue, 16 Jun 2026 08:31:43 -0400

Caris Life Sciences (NASDAQ: CAI) announced that its common stock will be dual-listed on NYSE Texas effective June 17, 2026, while continuing to trade on the NASDAQ as its primary exchange. The stock will carry the same CAI ticker symbol on both exchanges.

The Irving, Texas-based company said the dual listing is intended to provide additional exposure to investors, particularly within Texas and the broader U.S. market.

"Establishing a dual listing on NYSE Texas reflects both our continued growth as a public company and our deep roots in Texas, including our headquarters and over 450 Caris employees in the state," said David

Caris Life Sciences Announces Dual Listing on NYSE Texas

Tue, 16 Jun 2026 08:30:00 -0400

IRVING, Texas, June 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced the dual listing of its common stock on NYSE Texas effective on June 17, 2026, further expanding its presence in the public markets.

Caris Life Sciences Announces Dual Listing on NYSE Texas

Tue, 16 Jun 2026 08:30:00 -0400

Caris Life Sciences Announces Dual Listing on NYSE Texas

Tue, 16 Jun 2026 08:30:00 -0400